NM
FTH

Newtyn Management’s Faeth Therapeutics FTH Stock Holding History

Newtyn Management’s Portfolio FTH Stock Details FTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-46,512
Closed -$977K – 45
2024
Q1 		$977K Sell
46,512
-32,089
-41% -$553K 0.19% 37
2023
Q4 		$1.09M Sell
78,601
-11,399
-13% -$156K 0.21% 37
2023
Q3 		$1.35M Sell
90,000
-1,362
-1% -$29.3K 0.33% 35
2023
Q2 		$2.08M Buy
91,362
+14,316
+19% +$419K 0.49% 30
2023
Q1 		$2.31M Buy
77,046
+19,268
+33% +$571K 0.45% 45
2022
Q4 		$1.72M Buy
57,778
+37,028
+178% +$1.09M 0.36% 39
2022
Q3 		$643K Hold
20,750
– – 0.14% 62
2022
Q2 		$942K Buy
+20,750
New +$778K 0.18% 63

Other funds holding FTH

IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CAM
Cresset Asset Management Chicago, Illinois $27.6B AUM 31.92% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

Newtyn Management's FTH Position: Q2 2024 in Review

Newtyn Management sold out of Faeth Therapeutics (FTH) in Q2 2024, closing a stake of 46,512 shares — an estimated $977K sold.

Newtyn Management first reported a position in FTH in Q2 2022 and held it in 8 quarters. The position peaked at $2.31M in Q1 2023. 23 funds tracked by Wall St. Rank hold FTH as of Q2 2024.

  • Newtyn Management reported no remaining Faeth Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Newtyn Management sold 46,512 Faeth Therapeutics shares in Q2 2024, an estimated $977K.
  • Newtyn Management first reported a position in Faeth Therapeutics in Q2 2022 and held it in 8 quarters.
  • Newtyn Management's Faeth Therapeutics position peaked at $2.31M in Q1 2023.
  • 23 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q2 2024.

Based on Newtyn Management's 13F filing for Q2 2024, filed 14 Aug 2024.